Elsevier

Brain Research

Volume 620, Issue 1, 20 August 1993, Pages 163-166
Brain Research

Effect of aging in human cortical pre- and postsynaptic serotonin binding sites

https://doi.org/10.1016/0006-8993(93)90286-VGet rights and content

Abstract

5-HT1A, 5-HT1D, 5-HT2 binding sites and affinity and 5-HT uptake sites were simultaneously determined in frontal cortex samples from 23 control subjects, aged 16–75 years. A significant reduction in the number of 5-HT1D and 5-HT2 binding sites was found with regard to age, together with a significant decrease in the 5-HT2 binding affinity. It is suggested that the total 5-HT1 age-related loss described in previous studies could be ascribed to the 5-HT1D subtype. Furthermore, aging does not seem to be associated with a reduced cortical serotonergic innervation, as indicated by the stability of the [3H]paroxetine-labeled 5-HT uptake sites.

References (27)

  • AdhamN. et al.

    The rat 5-hydroxytryptamine-1B receptor is the species homologue of the human 5-hydroxytryptamine-1Dβ receptor

    Mol. Pharmacol.

    (1992)
  • AllenS.J. et al.

    Biochemical evidence for selective nerve cell changes in the normal ageing human and rat brain

    J. Neurochem.

    (1983)
  • BowenD.M. et al.

    Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease

    J. Neurochem.

    (1983)
  • Cited by (84)

    • Which demographic variables are necessary to correct in neuroimaging studies of serotonin transporter availability? A SPECT study with [<sup>123</sup>I]ADAM

      2015, Psychiatry Research - Neuroimaging
      Citation Excerpt :

      Also, the highly selective affinity of SERT as assessed with the [123I]ADAM radioligand mitigates against the possible confound of dual activity related to the dopamine transporter (DAT), which might otherwise influence the results, as DAT may be also influenced by age (Lavalaye et al., 2000). The influence of age on SERT was not conclusive in previous post-mortem (Allen et al., 1983; Arranz et al., 1993) or other in vivo neuroimaging studies (Dahlstrom et al., 2000; Buchert et al., 2006), and the lack of clarity may reflect limited sample sizes in previous studies and the use of different radioligands. In addition, the age range of the subject group may affect the results.

    • The serotonergic system in ageing and Alzheimer's disease

      2012, Progress in Neurobiology
      Citation Excerpt :

      However, other studies reported an age-associated increase in [3H]-imipramine binding site in the human hypothalamus, parietal cortex, frontal cortex, occipital cortex and the hippocampus (Owen et al., 1986; Severson et al., 1985). Moreover, binding studies using [3H]-paroxetine reported stable density of SERT expression in aged human frontal cortex (Arranz et al., 1993). On average, there is a 10% decrease per decade in the density of SERT binding sites in human brain stem and thalamus (Yamamoto et al., 2002).

    • [ <sup>11</sup>C]-DASB microPET imaging in the aged rat: Frontal and meso-thalamic increases in serotonin transporter binding

      2011, Experimental Gerontology
      Citation Excerpt :

      Regarding the effects of age on the 5-HTT, human postmortem studies have rendered quite inconclusive results. The majority of postmortem research on this topic observed no age-associated changes in 5-HTT levels (Andersson et al., 1992; Arranz et al., 1993), although several studies report regional increments (Severson et al., 1985) or decrements (Marcusson et al., 1987) as well. Molecular imaging studies in humans, however, have predominantly found reductions in 5-HTT radioligand uptake in the diencephalon and midbrain (Hesse et al., 2003; Kuikka et al., 2001; Pirker et al., 2000; Yamamoto et al., 2002), although not all in vivo studies observed this effect (Ryding et al., 2004).

    View all citing articles on Scopus

    The study was supported by grants from the Swedish Medical Research Council (B92-12X-08648-04B), the Stohne Foundation, Centrala Forsoksdjursnamnden and Gamla Tjanarinnor, the Swedish Society for Medicine, and FIS (93/0318).

    View full text